Browsing Tag
MPACT trial
2 posts
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates?
Amplia’s pancreatic cancer trial hits a 31% response rate, surpassing MPACT. Find out how it compares to POLO and what it means for future therapy options.